Fujian Genohope Biotech Ltd. was established in January 2019 by New Hope Life Science Investment Fund and Genovior Biotech Corporation. The business has a prime geographic location and easy access to transportation in the Fujian Putian Washi Industrial Park, which is close to the Fuxia Railway and Putian Station of the High-speed Highway. A one-stop pharmaceutical R & D and production outsourcing (CDMO) high-tech enterprise, the company has a total area of 55 acres and has constructed an advanced factory in accordance with PIC/S GMP international standards, focusing on Long-acting formulations of peptide drugs, anticancer drugs, biological drugs, and other APIs, as well as all corresponding injection development and production.

Outstanding individuals from the biotechnology and pharmaceutical sectors are brought together by Genohope Biotech to provide customers with contracted services including new drug candidate development, process validation, quality standards research and practice,  clinical trials, and commercial solutions, as well as data services for registration of chemicals, manufacturing, and regulatory controls. One of the few CRO, CDO, and CMO-capable one-stop injectable drug contract developers in Asia, Genohope Biotech is also one of the few teams with actual mass production expertise.

Genohope Biotech‘s production facility is capable of providing ready-for-launch dosage forms like injections, lyophilized goods, prefilled syringes and cartridges. Actively improving its presence in global market, Genohope Biotech will also soon offer one-stop biomedical R&D and production services for clients worldwide. We aim to become Asia's top one-stop contract developer and manufacturer of injectable drugs by offering customers convenient, useful, and efficient pharmaceutical finished product solutions aligned with high quality standards and assured safety.